NCT05873660Completed
A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease
Multi-centre Cross-sectional Observational Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease
Source: ClinicalTrials.gov · Last updated 11 Jul 2024
Brief summary (registry, in English)
The purpose of this observational study is to measure how many people are overweight or obese amongst patients with a diagnosed cardiovascular disease (CVD). The study also aims to characterise the population including the presence of cardiovascular (CV) risk factors in a number of countries across the globe representing different geographies, ethnicities, as well as different healthcare systems.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 5360 (actual)
- First submitted
- 15 May 2023
- Start date
- 12 Jun 2023
- Primary completion date
- 24 Jun 2024
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT05873660
What you commit to
- Study type: Observational
- Participants enrolled: 5360
- From 12 Jun 2023 to the primary completion date, 24 Jun 2024
- 5 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous participation in this study. Participation is defined as having given informed consent in this study
Other illness
- Patients with known congenital heart disease/malformation
Other
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Who the study is looking for
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Adults, age above or equal to 18 years at the time of signing informed consent.
- Have established CVD and equal to or greater than 1 follow up appointment following an acute event from at least one of the following:
- Prior myocardial infarction
- Prior stroke (ischemic or haemorrhagic stroke)
- Symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) below 85 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease
Age in the registry: 18 years to - · Sex: All
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Ontario | Canada | Unknown status |
| - Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| - Coordinator of this site? Confirm its status | Riyadh | Saudi Arabia | Unknown status |
| - Coordinator of this site? Confirm its status | Plainsboro | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.